Dupilumab: Evaluating its role in atopic dermatitis, prurigo nodularis, eczemas, urticaria, alopecia areata and vesiculobullous disorders

Dupilumab is a fully human monoclonal IgG4 antibody that targets IL-4 and IL-13 signaling pathways. It is approved by the US-FDA for the treatment of atopic dermatitis and prurigo nodularis. Besides, it has shown efficacy in various off-label dermatologic conditions. This review will elaborate on the utility of dupilumab in atopic dermatitis, prurigo nodularis, eczemas, urticaria, alopecia areata and vesiculobullous disorders.